CART treatment for blood cancers that came back
This trial tests a new treatment using your own immune cells (called CART cells) that are engineered to find and destroy cancer cells in certain types of B-cell blood cancers. It might help if standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of blood cancer called B-cell malignancy (like lymphoma) that is relapsed or refractory.
- You have not had CART treatment before (unless you are in a specific group).
- You have at least one measurable tumor that can be checked on scans.
- Your overall health is good enough for a clinical trial (doctors will check this).
- You are not pregnant, and if you can get pregnant, you must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses a virus to make your own immune cells attack two targets on cancer cells. It is for people with B-cell blood cancers that have come back or not responded to other treatments.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are made from a donor to attack cancer cells in people with B-cell blood cancers that have come back or not responded to standard treatments. The goal is to see if these cells can help people who haven't had success with other therapies.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This trial tests a new type of cell therapy (CAR T) that targets two markers on lymphoma cells, CD19 and CD22. It is for people with aggressive B-cell lymphoma that has not responded to standard treatments.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for patients with a specific kind of B-cell lymphoma that has come back or not responded to previous therapy. The treatment targets a protein called CD19 on the cancer cells to help your immune system fight the lymphoma.
Hear when a new Relapsed/Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.